Efficient Viral Vector Production Cell Line — PowerSTM-293/293T

By Chunling Xuan, Xiangyu Zang, Rongna Ding，Jane Liu, Davis Xie, Eric Lin, Moco Wang, Lance Marquardt

HEK 293 cell lines have become indispensable in cell and gene therapy manufacturing, particularly for producing adeno-associated virus (AAV) and lentiviral vectors (LVV). Their adaptability to suspension culture marks a major advancement, offering improved scalability and reduced production costs without compromising quality. Suspension-adapted HEK 293 platforms, such as PowerSTM-293/293T, deliver consistent, high-yield viral vector production across multiple serotypes and scales, supported by rigorous characterization and compliance with global regulatory standards including FDA, EMA, and NMPA.

Through systematic optimization using Design of Experiments (DoE), critical process parameters—such as viable cell density, plasmid ratios, and enhancer strategies—have been refined to maximize efficiency and reproducibility. These efforts enable robust scale-up from laboratory to bioreactor environments, ensuring stability over extended passages and minimizing risks associated with clonality.

For developers navigating IND submissions and GMP manufacturing, these advancements provide a reliable foundation for accelerating timelines and achieving regulatory milestones. Explore how optimized HEK 293 suspension systems are shaping the future of viral vector production and driving innovation in gene therapy.